KRAS G12C inhibition enhances efficacy to conventional chemotherapy in KRAS-mutant NSCLC
{{output}}
Despite recent therapeutic advances, the adjuvant treatment of non-small cell lung cancer (NSCLC) remains a challenge. Reducing the risk of recurrence is still a concern, especially in the KRAS G12C population, for which platinum-based adjuvant chemotherapy (C... ...
